DarioHealth Corp. (NASDAQ: DRIO) president and CCO on indefinite medical leave

Q: How is DARIOHEALTH CORP. (DRIO) handling Steven Nelson’s responsibilities during his leave?

DarioHealth states that members of the senior management team are assuming Steven Nelson’s responsibilities while he is on medical leave. This arrangement is intended to maintain operational continuity during his indefinite absence.

Q: What type of event did DARIOHEALTH CORP. (DRIO) report related to its executive team?

DarioHealth reported an executive leadership event , namely the extension of President and Chief Commercial Officer Steven Nelson’s temporary medical leave to an indefinite period, with senior management covering his responsibilities.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

DarioHealth Corp. reported that the temporary medical leave of absence of its President and Chief Commercial Officer, Steven Nelson, was extended on July 10, 2026 for an indefinite period. During his leave, the company states that his responsibilities are being handled by members of the senior management team.

Positive

None.

Negative

The President and Chief Commercial Officer’s medical leave has been extended for an indefinite period, creating leadership and commercial execution uncertainty.

Insights

Key commercial leader remains on indefinite medical leave, adding execution risk.

The extension of President and Chief Commercial Officer Steven Nelson's medical leave to an indefinite period removes a central commercial leader from day-to-day operations. Commercial strategy, sales execution, and key customer relationships often sit with this role.

The company notes that senior management is assuming his responsibilities, which can support continuity but may stretch existing leaders and slow decision-making. Investors may pay attention to any later update on leadership structure or a defined timeline for his return or replacement.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Key Terms

medical leave of absence, President and Chief Commercial Officer, Emerging growth company

3 terms

medical leave of absence regulatory

"the temporary medical leave of absence of Steven Nelson"

President and Chief Commercial Officer financial

"Steven Nelson, President and Chief Commercial Officer of DarioHealth Corp."

Emerging growth company regulatory

"Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Understanding 8-K Material Events →

Available on EDGAR 07/10/2026 - 05:10 PM Accepted by SEC EDGAR 07/10/2026 - 05:10 PM

FAQ

What leadership change did DARIOHEALTH CORP. (DRIO) disclose on July 10, 2026?

DarioHealth disclosed that President and Chief Commercial Officer Steven Nelson's temporary medical leave of absence was extended for an indefinite period. The company stated that members of its senior management team are assuming his responsibilities during this leave.

Is Steven Nelson still serving as President and Chief Commercial Officer of DRIO?

Steven Nelson remains President and Chief Commercial Officer of DarioHealth but is on an extended medical leave of absence for an indefinite period. His responsibilities are currently being handled by the company’s senior management team.

How is DARIOHEALTH CORP. (DRIO) handling Steven Nelson’s responsibilities during his leave?

DarioHealth states that members of the senior management team are assuming Steven Nelson’s responsibilities while he is on medical leave. This arrangement is intended to maintain operational continuity during his indefinite absence.

Does the DRIO disclosure specify when Steven Nelson will return from medical leave?

No specific return date is provided; the company states that Steven Nelson’s medical leave has been extended for an indefinite period. His responsibilities will remain with senior management while this leave continues.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): July 10, 2026

DARIOHEALTH CORP.

(Exact name of registrant as specified in its charter)

Delaware		001-37704		45-2973162
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

322 W 57th St., #33B
New York, New York 10019 (Address of Principal Executive Offices)

972- 4-770-6377

(Issuer’s telephone number)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of exchange on which registered
Common Stock, par value $0.0001 per share		DRIO		The Nasdaq Capital Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On July 10, 2026, the temporary medical leave of absence of Steven Nelson, President and Chief Commercial Officer of DarioHealth Corp., or the Company, was extended for an indefinite period. During Mr. Nelson’s leave of absence, his responsibilities are being assumed by members of the Company’s senior management team.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: July 10, 2026	DARIOHEALTH CORP.

	By:	/s/ Chen Franco-Yehuda
	Name:	Chen Franco-Yehuda
	Title:	Chief Financial Officer, Treasurer and Secretary

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

3 documents